Axxonis submits MAA for Nenad

Berlin, Germany-based Axxonis Pharma AG has submitted a Marketing Authorization Application to the European Medicines Agency (EMEA) for Nenad (lisuride) transdermal patch as add-on therapy for Parkinson's disease and for Restless Legs Syndrome, and subcutaneous lisuride infusion for advanced PD.

Lisuride is a potent dopamine agonist which in its parenteral forms (transdermal patch and sc infusion) has been developed to provide continuous dopaminergic stimulation. Experts expect from CDS a new quality of treatment of PD and RLS combined with ease of administration. All results obtained so far not only demonstrate strong efficacy, but also a good general tolerability of Nenad and an improved quality of life for those affected by these neurological conditions, the company claims.